Recent Updates
Recently added Catalysts
LUNG Positive Sentiment

Pulmonx to Participate in the Piper Sandler 38th Annual Healthcare Conference

Key Takeaway: Pulmonx Corporation will participate in the Piper Sandler 38th Annual Healthcare Conference on December 2, 2026. The event will include a fireside discussion and in-person investor meetings. A live and archived webcast will be accessible on the company's website, enhancing investor engagement.

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in a major healthcare conference
  • Hosting in-person investor meetings
  • Live webcast available for broader audience
  • Company recognized as a leader in lung disease treatments

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~49 mo
Low dilution risk
Lead asset
Chartis System
Phase 2 · Heterogeneous Emphysema

Full Press Release Details

REDWOOD CITY, Calif., Nov. 18, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside discussion at the Piper Sandler 38th Annual Healthcare Conference in New York City on Wednesday, December 2, 2026, at 1:30 PM PT / 4:30 PM ET. The company will also be hosting in-person investor meetings.
A live and archived webcast of the fireside discussion will be available on “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.
About Pulmonx Corporation Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System, LungTraX® Platform, and StratX® Lung Analysis Reports are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received U.S. Food and Drug Administration (FDA) Premarket Approval (PMA) to commercialize the Zephyr® Endobronchial Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com. Pulmonx®, AeriSeal®, Chartis®, LungTraX®, StratX®, and Zephyr® are registered trademarks of Pulmonx Corporation.

Frequently Asked Questions

When is Pulmonx participating in the conference?

Pulmonx will participate on December 2, 2026.

What will Pulmonx discuss at the conference?

The company will have a fireside discussion.

Will there be investor meetings?

Yes, Pulmonx will host in-person investor meetings.

How can I access the webcast?

The webcast will be available on Pulmonx's website.

Last updated: Nov 18, 2026